Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Clinical Trial
95%
Advanced Cancer
85%
Neoplasm
71%
Solid Malignant Neoplasm
69%
Diseases
69%
Overall Survival
35%
Bevacizumab
32%
Adverse Event
30%
Acute Myeloid Leukemia
30%
Chronic Lymphatic Leukemia
29%
Progression Free Survival
28%
Fludarabine
27%
Phase I Trials
24%
Cytarabine
23%
Remission
23%
Paclitaxel
23%
Maximum Tolerated Dose
20%
Vasculotropin
19%
Epidermal Growth Factor Receptor
18%
Oxaliplatin
17%
Chemotherapy
17%
Selinexor
16%
Gemtuzumab Ozogamicin
16%
Thrombocytopenia
16%
Colorectal Carcinoma
15%
Mammalian Target of Rapamycin Inhibitor
14%
Non Small Cell Lung Cancer
14%
Lenalidomide
13%
Melanoma
13%
Combination Therapy
13%
Syndrome
13%
Antitumor Activity
13%
Cetuximab
12%
Carboplatin
11%
Pharmacokinetic
11%
Breast Cancer
11%
Neutropenia
11%
Anemia
10%
Sorafenib
10%
Diarrhea
10%
Biological Marker
9%
Metastasis
9%
Ovary Cancer
9%
Vemurafenib
9%
Rituximab
8%
Pancreas Cancer
8%
Rash
8%
Mitoxantrone
8%
Pembrolizumab
8%
Keyphrases
Patients with Advanced Cancer
68%
Phase I Clinical Trial
48%
Stable Disease
47%
Partial Response
38%
Advanced Solid Tumors
37%
Phase I Study
35%
Bevacizumab
30%
MD Anderson Cancer Center
30%
Phase I Trial
29%
Dose-limiting Toxicity
27%
Chronic Lymphocytic Leukemia
25%
Center Experience
22%
Targeted Therapy
22%
Advanced Cancer
22%
Acute Myeloid Leukemia
21%
Clinical Outcomes
19%
Maximum Tolerated Dose
19%
Cytarabine
19%
Overall Survival
18%
PIK3CA mutation
18%
Confidence Interval
17%
Paclitaxel
17%
Fludarabine
17%
Clinical Trials
17%
MTOR Inhibitor
17%
Tumor
17%
Early Phase Clinical Trials
17%
Solid Tumors
16%
Non-small Cell Lung Cancer (NSCLC)
15%
Selinexor
15%
Tumor Subtype
14%
Dose Level
14%
Progression-free Survival
14%
Cancer Center
14%
Oxaliplatin
14%
Dose-escalation Study
14%
Thrombocytopenia
14%
Metastatic Tumor
13%
Cetuximab
13%
Lenalidomide
13%
Richter Syndrome
13%
Median Overall Survival
12%
KRAS mutation
12%
Antitumor Activity
12%
Median Progression-free Survival
12%
Hepatic Arterial Infusion
11%
Chemotherapy
11%
Adverse Events
11%
Temsirolimus
11%
Complete Remission
11%
Medicine and Dentistry
Malignant Neoplasm
78%
Clinical Trial
76%
Neoplasm
74%
Advanced Cancer
58%
Targeted Therapy
42%
Cancer
39%
Diseases
36%
Oncology
32%
Personalized Medicine
31%
Overall Survival
30%
Solid Malignant Neoplasm
25%
Progression Free Survival
25%
B-Cell Chronic Lymphocytic Leukemia
23%
Acute Myeloid Leukemia
18%
Next Generation Sequencing
17%
Immunotherapy
15%
Biological Marker
15%
Metastatic Carcinoma
14%
Cancer Therapy
14%
Mammalian Target of Rapamycin Inhibitor
13%
Molecular Profiling
13%
Cell-Free DNA
12%
Phase I Trials
12%
Vasculotropin
12%
Adverse Event
11%
Circulating Tumor DNA
11%
Bevacizumab
11%
Fludarabine
11%
Colorectal Carcinoma
10%
Ovarian Cancer
10%
Lymphocytic Lymphoma
10%
Epidermal Growth Factor Receptor
10%
Melanoma
10%
Multivariate Analysis
10%
Breast Cancer
10%
PI3K/AKT/mTOR Pathway
9%
Clinical Oncology
9%
Hepatic Arterial Infusion
9%
Non Small Cell Lung Cancer
9%
T Cell
9%
Hazard Ratio
9%
Arm
9%
Systemic Therapy
8%
DNA Determination
8%
Pembrolizumab
8%
Oxaliplatin
8%
Paclitaxel
8%
Pathologist
7%
Selinexor
7%
Rituximab
7%